Q4FY24 EARNING CALENDAR AT A GLANCE

અમદાવાદ, 28 મેઃ માર્ચ-24ના અંતે પુરાં થયેલા ચોથા ત્રિમાસિક ગાળા માટે આજે જાહેર થનારા મહત્વના કંપની પરીણામો અંગે બજાર નિષ્ણાતો, બ્રોકરેજ હાઉસ તથા ફંડ હાઉસ દ્વારા અંદાજો વ્યક્ત કરાયા છે. તે રોકાણકારોના અભ્યાસ માટે અત્રે રજૂ કરીએ છીએ.

28.05.2024: 3MINDIA, ABFRL, ARE&M, BRIGADE, CAMPUS, CAPACITE, DREAMFOLKS, DYNAMATECH, EIHOTEL, ENGINERSIN, EPL, EUREKAFORBE, EXICOM, GICRE, GENSOL, GNFC, GOODLUCK, GRAUWEIL, IMAGICAA, INDIAGLYCO, IRCTC, ITDCEM, ITI, LINDEINDIA, MANINDS, MEDPLUS, MMTC, MTARTECH, NBCC, NFL, PARKHOTELS, PRESTIGE, RITES, RRKABEL, SEPC, SHALBY, UFLEX, UGARSUGAR, UNIPARTS

ABFRL

Revenue expected at Rs 3335 crore versus Rs 2879 crore

EBITDA expected to be seen at Rs 274 crore versus Rs 192 crore

EBITDA margin expected to be seen at 8.21% versus 6.70%

Net Loss expected to be seen at Rs 265 crore versus Rs 186 crore

ENGINERSIN

Revenue expected at Rs 1121 crore versus Rs 868 crore

EBITDA expected to be seen at Rs 63 crore versus Rs 110 crore

EBITDA margin expected to be seen at 5.62% versus 12.6%

Net profit expected to be seen at Rs 133 crore versus Rs 50 crore

IRCTC

Revenue expected at Rs 1145 crore versus Rs 965 crore

EBITDA expected to be seen at Rs 394 crore versus Rs 325 crore

EBITDA margin expected to be seen at 35.24% versus 33.67%

Net profit expected to be seen at Rs 310 crore versus Rs 279 crore

PRESTIGE

Revenue expected at Rs 2877 crore versus Rs 2631 crore

EBITDA expected to be seen at Rs 746 crore versus Rs 681 crore

EBITDA margin expected to be seen at 25.93% versus 25.91%

Net profit expected to be seen at Rs 302 crore versus Rs 458 crore

RITES

Revenue expected at Rs 677 crore versus Rs 686 crore

EBITDA expected to be seen at Rs 166 crore versus Rs 191 crore

EBITDA margin expected to be seen at 24.5% versus 27.9%

Net profit expected to be seen at Rs 123 crore versus Rs 138 crore

29.05.2024: AADHARHFC, AHLUCONT, ALKEMLAB, ASHAPURMIN, BATAINDIA, CUMMINSIND, DBREALTY, DEEPAKFERT, DONEAR, EMAMILTD, ENTERO, FDC, GENUSPOWER, GMRINFRA, HCG, HINDOILEXP, INNOVACAP, IONEXCHANG, IPCALAB, ISGEC, JUBLPHARMA, KIOCL, KNRCON, LEMONTREE, MAZDOCK, MIDHANI, MOTHERSON, MUNJALSHOW, NOCIL, RAMKY, SAMHI, SJVN, SOLARA, TATASTEEL, WEBELSOLAR, ZUARIIND

(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)